论文部分内容阅读
目的:对比氟康唑和阿尼芬净在白念珠菌感染治疗中的疗效,为临床真菌感染药物的选择提供依据。方法:对135例白念珠菌感染的患者进行了研究,比较2组患者在静脉注射氟康唑/阿尼芬净治疗结束时的总体反应率,分析了血培养转阴的时间、静脉治疗结束后的持续性感染情况和6周的存活情况。结果:阿尼芬净的总体反应明显好于氟康唑(81.1%vs62.3%;95%置信区间[CI]差异,3.7～33.9),阿尼芬净与较快的血培养清除率显著相关(对数秩P<0.05)并且与较低的持续性感染相关(2.7%vs 13.1%;P<0.05),2组患者6周后存活情况无差异。结论:对白色念珠菌感染的患者来说,阿尼芬净比氟康唑的效果更好,能够更快使阳性血培养转阴。研究表明阿尼芬净可替代氟康唑作为临床治疗常见真菌感染的一线药物。
Objective: To compare the efficacy of fluconazole and anidulafungin in the treatment of Candida albicans infection, and provide evidence for the selection of clinical fungal infections. Methods: A total of 135 Candida albicans-infected patients were studied. The overall response rate was compared between the two groups at the end of the intravenous fluconazole / anivanine treatment. The timing of negative blood cultures was analyzed, and venous treatment was terminated After persistent infection and 6 weeks of survival. RESULTS: The overall response to anidulafungin was significantly better than fluconazole (81.1% vs62.3%; 95% confidence interval [CI] difference, 3.7-33.9), and significant differences were observed between anidulafungin and faster blood culture clearance (Log rank P <0.05) and was associated with lower persistent infection (2.7% vs 13.1%; P <0.05). There was no difference in survival after 6 weeks in both groups. CONCLUSIONS: Anidulafungine is more effective than fluconazole in patients with Candida albicans infection and can make positive blood cultures more negative sooner. Studies have shown that anifen net can replace fluconazole as a first-line drug for clinical treatment of common fungal infections.